Secondary Logo

Institutional members access full text with Ovid®

Share this article on:


Seider, Michael, I., MD*,†; Mruthyunjaya, Prithvi, MD, MHS

doi: 10.1097/IAE.0000000000001757

Purpose: To review laboratory methods, currently available commercial tests, caveats and clinical tips regarding prognostic analysis of uveal melanoma tissue.

Methods: A review of the literature was performed focused on the genetic abnormalities found in uveal melanoma cells, their correlation to the development of metastases, the validity of various laboratory approaches in their detection, and the existing commercially available tests for uveal melanoma prognostication.

Results: Numerous laboratory methods exist for analyzing genetic material obtained from uveal melanoma cells. Older tests have been gradually replaced with contemporary methods that are simpler with greater accuracy. Two commercially available assays exist which have not been directly compared—a gene expression profiling test has been validated directly through a large, prospective multicenter study and a DNA-based test which uses laboratory methods supported by extensive historical data.

Conclusion: There are myriad laboratory methods for prognostic analysis of uveal melanoma tissue. These tests were historically only available to those with access to an outfitted laboratory. Newer commercially available assays have increased the accessibility of prognostic biopsy for uveal melanoma. The various caveats that exist when considering and performing prognostic biopsy of uveal melanoma are discussed.

This review discusses the laboratory methods, the currently available commercial tests, and clinical tips regarding prognostic analysis of uveal melanoma tissue.

*Department of Ophthalmology, The Permanente Medical Group, San Francisco, California; and

Department of Ophthalmology, University of California, San Francisco, California.

Reprint requests: Prithvi Mruthyunjaya, MD, MHS, Stanford Byers Eye Institute, 2452 Watson Ct MC 5353, Palo Alto, CA 94303; e-mail:

Michael I. Seider does not have any financial/conflicting interests to disclose. Prithvi Mruthyunjaya is a consultant for Castle Biosciences, Inc.

© 2018 by Ophthalmic Communications Society, Inc.